Legend Biotech Corp
NASDAQ:LEGN
Legend Biotech Corp
NASDAQ:LEGN
Price:
45.3 USD
1.98%
Market Closed
Updated:
Apr 28, 2024
Legend Biotech Corp
Cash from Financing Activities
|
Legend Biotech Corp
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Legend Biotech Corp
NASDAQ:LEGN
|
Cash from Financing Activities
$791.5m
|
CAGR 3-Years
9%
|
CAGR 5-Years
216%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Legend Biotech Corp's Cash from Financing Activities?
Cash from Financing Activities
791.5m
USD
791.5m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Cash from Financing Activities amounts to 791.5m USD.
What is Legend Biotech Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
216%
216%
Over the last year, the Cash from Financing Activities growth was 109%. The average annual Cash from Financing Activities growth rates for Legend Biotech Corp have been 9% over the past three years , 216% over the past five years .
You don't have any saved screeners yet
